1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Advance Biotech Grant Program is sponsored by MilliporeSigma (part of Merck KGaA). This program recognizes emerging biopharmaceutical and biotech startups and provides them with products, services, and consultation to advance production and accelerate the path to commercialization. While focused on startups, university spin-offs or research groups with a clear path to commercialization in biotechnology could be considered.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Emerging biopharmaceutical and biotech startups. Description of therapeutic focus and clinical strategy is required. Confirm the full requirements in the official notice before applying.
Advance Biotech Grant Program is funded by MilliporeSigma (part of Merck KGaA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The RUS Powering Affordable Reliable Technology (PART) Energy Program takes Letters of Interest until October 9, 2026. Up to 40% of each loan can be forgiven, awards run $1M to $100M, and USDA describes eligible generation as hydro, geothermal, and biomass — even though Section 317 of the RE Act names solar and wind.
Read articleThe Rural Utilities Service is putting $410 million of Section 22001 budget authority back in the market through the Powering Affordable Reliable Technology program. Letters of Interest open September 8 and close October 9, 2026 — both at 11:59 a.m., not p.m. — and RUS evaluates them on a rolling basis in the order received.
Read articleOMB's proposed rewrite of the Uniform Guidance would let political appointees pre-screen every discretionary grant, terminate active awards 'in the interest of the agency' with a brief note, and bar whole categories of costs. It drew nearly 500,000 comments and takes effect October 1, 2026. Here is what actually changes at the section level, who is exposed, and how to prepare now.
Read article